hit counter
Adverum Biotechnologies, Inc. (ADVM) Stock News Sentiment & Price - Sentifly
ADVM - Sentifly


Profile

Watchlist

Your watchlist is empty. Go add some tickers to it!



Adverum Biotechnologies, Inc. (ADVM)

USA
Biotechnology
NASDAQ
ADVM Price and Sentiment
1MO
1D
Positive, Negative
Loading chart...
ADVM Latest news
GlobeNewsWire
Neutral
Adverum Reports Third Quarter 2021 Results
2021-11-04 16:05

REDWOOD CITY, Calif., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today reported financial results for the third quarter ending September 30, 2021 and provided a business update.

PennyStocks
Positive
Best Penny Stocks To Buy This Week? 10 With Potential Biotech Catalysts
2021-10-10 10:45

Are these 10 penny stocks on your watch list this week? The post Best Penny Stocks To Buy This Week?

GlobeNewsWire
Neutral
Adverum Presents Clinical Data on ADVM-022 at the American Society of Retina Specialists 39th Annual Scientific Meeting
2021-10-09 11:17

-- Company maintains focus on advancing ADVM-022 at low doses in patients with wet AMD -- -- Company maintains focus on advancing ADVM-022 at low doses in patients with wet AMD --

Benzinga
Positive
Adverum's Single Dose Wet AMD Gene Therapy Shows Robust Two Year Durability, Safety
2021-10-04 06:49

Adverum Biotechnologies Inc (NASDAQ: ADVM) announced new long-term data from the OPTIC trial of ADVM-022 gene therapy for neovascular or wet age-related macular degeneration (wet AMD). Data were shared at the Retina Society's Annual Scientific Meeting.

Pulse2
Positive
ADVM Stock: Why It Increased Today
2021-10-04 06:11

The stock price of Adverum Biotechnologies, Inc. (Nasdaq: ADVM) increased by over 10% pre-market today. This is why it happened.

PennyStocks
Positive
5 Penny Stocks To Watch This Week With Potential Biotech Catalysts
2021-10-03 10:45

Will upcoming events mean big things for these penny stocks? The post 5 Penny Stocks To Watch This Week With Potential Biotech Catalysts appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

GlobeNewsWire
Neutral
Adverum Presents 2-Year OPTIC Data Demonstrating Sustained Durability and Promising Safety Profile from Single Intravitreal Injection of ADVM-022 in Wet AMD Patients Who Previously Required Frequent Anti-VEGF Injections
2021-10-01 16:00

-- Results featured in a presentation today at the Retina Society's 54 th Annual Scientific Meeting -- -- Robust aflibercept protein expression sustained through 2 years --

GlobeNewsWire
Neutral
Adverum to Present Data from ADVM-022 Clinical Trials at Upcoming Medical Conferences
2021-09-27 09:00

REDWOOD CITY, Calif., Sept. 27, 2021 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced the presentation of new clinical data on ADVM-022 intravitreal (IVT) injection gene therapy from the OPTIC trial in wet age-related macular degeneration (wet AMD) and the INFINITY trial in diabetic macular edema (DME) at upcoming medical conferences. Adverum is planning clinical development of ADVM-022 at the 2 x 10^11 vg/eye and a lower dose in patients with wet AMD. As previously disclosed, the company is no longer planning to develop ADVM-022 in DME.

GlobeNewsWire
Neutral
Adverum Appoints Global Regulatory Leader Jim Wang, Ph.D., as Senior Vice President, Head of Regulatory Affairs
2021-08-23 09:00

REDWOOD CITY, Calif., Aug. 23, 2021 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced that Jim Wang, Ph.D., has been appointed senior vice president, head of regulatory affairs. Reporting directly to Laurent Fischer, M.D., Adverum's president and chief executive officer, Dr. Wang will lead regulatory strategies and execution for the company's product pipeline. He brings more than 17 years of global regulatory experience, including a decade in gene therapy that includes the submission and approval for LUXTURNA®, the first gene therapy targeting a genetic disease that received regulatory approval in both the U.S. and EU.

Zacks Investment Research
Positive
Why Adverum Biotechnologies (ADVM) Might Surprise This Earnings Season
2021-08-06 11:30

Adverum Biotechnologies (ADVM) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Loading more news...